Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology.
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Eur J Cancer. 2020 Nov;139:192-200. doi: 10.1016/j.ejca.2020.08.003. Epub 2020 Sep 17.
TNM-8 staging separates oropharyngeal squamous cell carcinomas (OPSCC) into human papillomavirus (HPV)-mediated and -unrelated OPSCC based on p16INK4a overexpression (p16+), as surrogate marker for HPV. However, OPSCC is histologically and clinically heterogenous including tonsillar and base of tongue squamous cell carcinomas (TSCC and BOTSCC respectively), and carcinomas of soft palate and walls (otherOPSCC). The significance of HPV is established in TSCC/BOTSCC, while its role in otherOPSCC is unclear, which is not considered in TNM-8. Here, p16+ was therefore evaluated in relation to overall survival (OS) and tumor stage per OPSCC subsite.
All 932 patients, treated with curative intent in Stockholm 2000-2016 with OPSCC, previously analyzed for p16 expression, were included. Clinical data, including stage and OS, was collected retrospectively.
Patients with p16+ otherOPSCC had significantly poorer OS compared to patients with p16+ TSCC/BOTSCC (p = 0.005) and their survival was similar to that of patients with p16-otherOPSCC/TSCC/BOTSCC. Moreover, patients with TNM-8 stage I-II and p16+ otherOPSCC had a significant poorer OS compared to patients with p16+ TSCC/BOTSCC and similar stage (p = 0.02). Lastly, patients with otherOPSCC and low TNM-7 stage had a significant better OS, as compared to those with a high stage (p = 0.019) while no hazard discrimination was observed with TNM-7 in TSCC/BOTSCC.
Our results indicate a risk of misclassification of patients with otherOPSCC and low TNM-8 stage. We suggest that p16 should only be evaluated in TSCC/BOTSCC and that patients with otherOPSCC should all be staged as patients with HPV-unrelated (p16-) OPSCC.
TNM-8 分期根据 p16INK4a 过表达(p16+)将口咽鳞状细胞癌(OPSCC)分为 HPV 介导和不相关的 OPSCC,作为 HPV 的替代标志物。然而,OPSCC 在组织学和临床上具有异质性,包括扁桃体和舌根鳞状细胞癌(分别为 TSCC 和 BOTSCC)以及软腭和壁的癌(其他 OPSCC)。HPV 在 TSCC/BOTSCC 中的意义已经确立,而其在其他 OPSCC 中的作用尚不清楚,这在 TNM-8 中并未考虑。因此,本研究评估了 p16+与 OPSCC 各亚部位的总生存(OS)和肿瘤分期的关系。
所有 932 例于 2000-2016 年在斯德哥尔摩接受根治性治疗的 OPSCC 患者均进行了 p16 表达分析,包括 p16+其他 OPSCC 患者,均纳入本研究。回顾性收集临床数据,包括分期和 OS。
p16+其他 OPSCC 患者的 OS 明显低于 p16+ TSCC/BOTSCC 患者(p=0.005),与 p16-其他 OPSCC/TSCC/BOTSCC 患者的生存相似。此外,TNM-8 Ⅰ-Ⅱ期和 p16+其他 OPSCC 患者的 OS 明显低于 p16+ TSCC/BOTSCC 且分期相似的患者(p=0.02)。最后,与高分期患者相比,其他 OPSCC 且低 TNM-7 分期患者的 OS 显著更好(p=0.019),而 TNM-7 在 TSCC/BOTSCC 中未观察到危险分层。
我们的结果表明,其他 OPSCC 和低 TNM-8 分期患者存在分类错误的风险。我们建议仅在 TSCC/BOTSCC 中评估 p16,并将所有其他 OPSCC 患者分期为 HPV 不相关(p16-)OPSCC。